The effect of aspirin on duration of hemodialysis Graft patency time in patients with end stage renal disease (ESRD)
Phase 3
Recruiting
- Conditions
- End Stage Renal Disease.End stage renal diseaseN18.6
- Registration Number
- IRCT20200530047604N1
- Lead Sponsor
- Zanjan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
The desire to participate in the study
Age over 18 years
Need hemodialysis or undergoing hemodialysis
Not taking anti-coagulant drugs
Exclusion Criteria
Pregnant or lactating women
Patients at high risk of bleeding
Patients with platelet counts less than 7500 ml
Patients with liver disease and other advanced diseases
Patients need anticoagulants other than aspirin
Patients with dead gastritis before the examination
In case of severe complications in the patient due to aspirin use
Cerebral hemorrhagic diseases
Gastrointestinal bleeding disorders
Bleeding diseases
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Graft patency. Timepoint: Monthly for one year. Method of measurement: Decreased blood flow will be assessed by touch or listening, as well as when the dialysis needle is inserted into the graft during hemodialysis.
- Secondary Outcome Measures
Name Time Method